SBFM · Sunshine Biopharma Inc. Common Stock
View on chartInsiders & Stakes
| Sebaaly Camille CFO/Secretary | ▲ Buy | Open Market | 174,465 Shares held | 11/30/2022 | View profile |
| Slilaty Steve N. Chief Executive Officer | ▲ Buy | Open Market | 130,000 Shares held | 3/4/2024 | View profile |
| David Natan Director | ▲ Buy | Grant | 68,300 Shares held | 8/7/2026 | View profile |
Transaction History
| David Natan | ▲ Buy | Grant | 58,300 | $0 | 8/7/2026 |
| David Natan | ▲ Buy | Grant | 100,000 | $0 | 4/14/2026 |
| Slilaty Steve N. | ▲ Buy | Open Market | 100,000 | $10K | 3/4/2024 |
| Slilaty Steve N. | ▲ Buy | Open Market | 20,000 | $2K | 2/8/2024 |
| Sebaaly Camille | ▲ Buy | Open Market | 30,000 | $23K | 11/30/2022 |
| Sebaaly Camille | ▲ Buy | Open Market | 25,000 | $31K | 6/3/2022 |
| Slilaty Steve N. | ▼ Sell | Other | 990,000 | $99K | 2/18/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Sunshine Biopharma Amends Charter for Reverse Split
Sunshine Biopharma has amended its articles of incorporation to permit a reverse stock split of up to 1-for-20. The company's board of directors retains discretion on whether and when to execute this action. This move typically aims to adjust the share price to meet listing requirements or improve market perception.
Sunshine Biopharma Amends Charter for Reverse Split. Sunshine Biopharma has amended its articles of incorporation to permit a reverse stock split of up to 1-for-20. The company's board of directors retains discretion on whether and when to execute this action. This move typically aims to adjust the share price to meet listing requirements or improve market perception.